Big Cypress Acquisition Corp.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Big Cypress Acquisition Corp is a special purpose acquisition company (SPAC) established in 2020 and headquartered in Delaware. It focuses primarily on facilitating mergers and acquisitions in the biopharmaceutical sector by seeking innovative healthcare-related businesses with novel products or platforms addressing unmet medical needs. The company itself does not manufacture or sell products; instead, it operates by identifying and merging with target firms to bring them public. In a major recent development, Big Cypress Acquisition Corp completed a reverse merger with SAB Biotherapeutics, Inc. in October 2021. SAB Biotherapeutics is a clinical-stage biopharmaceutical company specializing in immunotherapies developed through its proprietary transchromosomic bovine platform for producing fully human polyclonal antibody therapeutics targeting various immune system disorders, cancer, and infectious diseases. Post-merger, Big Cypress Acquisition Corp adopted the SAB Biotherapeutics name and continues to operate under SAB’s management team. This strategic business combination marked a significant shift from being a blank check company to an active biopharmaceutical entity, expanding its operations into research, development, and commercialization of novel immunotherapy products targeting multiple disease indications primarily in the United States and global markets. The transaction was valued at approximately $118 million, and SAB Biotherapeutics plans to leverage proceeds to advance its clinical pipeline and commercialization goals. Prior to this change, Big Cypress Acquisition Corp had positioned itself as a platform for acquiring and taking innovative biopharmaceutical companies public, leveraging its industry relationships and capital base to enable growth in healthcare innovation. The company’s transition into SAB Biotherapeutics represents both an operational transformation and a focus on expanding the reach of a unique antibody technology platform. There have been no other major acquisitions or operational changes reported beyond this merger since 2021. The company’s origins as a SPAC and subsequent transformation through the acquisition of a clinical-stage biopharmaceutical firm with a distinctive product development platform underline its core business activities—facilitating capital markets access for promising healthcare innovators and now focusing on therapeutic product development and commercialization under the SAB brand. This description integrates Big Cypress Acquisition Corp’s founding as a SPAC, its business combination with SAB Biotherapeutics, and the latest strategic shift to operate as a clinical-stage biopharmaceutical company that develops and commercializes antibody-based immunotherapies using a genetically engineered bovine platform primarily serving markets in the United States and globally. The headquarters location is Delaware, with broader operational focus linked to SAB Biotherapeutics’ biopharmaceutical activities.
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below Two Hundred Day Moving Average – What’s Next?
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Pass Below 200-Day Moving Average – Here’s What Happened
Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Big Cypress Acquisition (OTCMKTS:BCYP) Stock Price Crosses Above 50-Day Moving Average – Here’s Why
Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Big Cypress Acquisition (OTCMKTS:BCYP) Shares Cross Below Fifty Day Moving Average – Here’s Why
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases